Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226791 · ClinicalTrials.gov registry record · Phase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
A Phase 2 study of Ventral Hernia, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT07226791: Recruiting Phase 2 study of Ventral Hernia, sponsored by AbbVie.
NCT07226791 is a Phase 2 study of Ventral Hernia that is actively recruiting participants, run by AbbVie. The registered enrollment target is 200 participants, above the 132-participant average among 18 other Ventral Hernia trials with a reported enrollment target (52% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226791, a Phase 2 study of Ventral Hernia, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed. AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States. Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Primary Outcome
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
Conditions Studied
Interventions
- DRUG AGN-151607-DP
- DRUG Placebo for AGN-151607-DP
Study Locations (2)
Florida
- Medical Research Center /ID# 278680 - Miami
Wisconsin
- NextStage Clinical Research-Evergreen Surgical /ID# 278710 - Eau Claire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-02-04 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
What NCT07226791 shows while recruiting
NCT07226791 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 18 other Ventral Hernia trials with a reported enrollment target (52% higher).
The record links to 1 condition, with Ventral Hernia appearing as the primary indexed condition, and to 2 interventions - of which AGN-151607-DP is the first listed.
NCT07226791 reports a single indexed study location in Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07226791 about?
NCT07226791 is a clinical study titled "Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair". A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closin...
What is the current status of trial NCT07226791?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-02-04. Estimated completion is 2030-05.
What conditions does trial NCT07226791 study?
This clinical trial studies the following conditions: Ventral Hernia.
What interventions are being tested in trial NCT07226791?
The interventions under investigation include: AGN-151607-DP (DRUG), Placebo for AGN-151607-DP (DRUG).
Who is sponsoring clinical trial NCT07226791?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226791 being conducted?
This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ventral Hernia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226791's enrollment target sits among peer trials
200 3rd of 18 higher than 14 of 18 other Ventral Hernia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ventral Hernia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair
RECRUITING · NA
-
Robotic Versus Open Ventral Hernia Repair
RECRUITING · NA
-
Clinical Investigation of the da Vinci Surgical System
ACTIVE NOT RECRUITING · NA
-
Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs
ACTIVE NOT RECRUITING · Early Phase 1
-
Methocarbamol in Ventral and Inguinal HR
ACTIVE NOT RECRUITING · Phase 4
-
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Hernia Surgery (Enable Hernia Repair)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI